skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Radioimmunoassay for bupropion in human plasma: comparison of tritiated and iodinated radioligands

Journal Article · · Clin. Chem. (Winston-Salem, N.C.); (United States)
OSTI ID:5998200

We evaluated the potential usefulness of /sup 125/I-labeled p-hydroxybupropion in a direct radioimmunoassay for bupropion in human plasma as compared with a currently used (/sup 3/H)bupropion dextran-coated charcoal method. In both radioimmunoassay methods succinoylpropylbupropion antiserum was used that was highly specific for unchanged drug, cross reactivities with known bupropion metabolites being less than 0.3%. However, the use of /sup 125/I-labeled p-hydroxybupropion afforded greater sensitivity (0.3 microgram/L vs 0.6 microgram/L with (/sup 3/H)bupropion) and was readily adaptable to the more convenient polyethylene glycol separation method. Between-assay CVs were 3.8 to 12.2% (mean 7.6%) with the /sup 125/I-based radioimmunoassay and 5.1 to 11.5% (mean 7.5%) with the /sup 3/H-based assay. Agreement between the two radioimmunoassay determinations of buproprion in human plasma samples collected over a 60-h period after oral drug administration was excellent (slope . 1.086, r . 0.989). We find the /sup 125/I-based assay a convenient and suitable alternative to the (/sup 3/H)bupropion assay in pharmacokinetic studies in humans.

Research Organization:
Department of Medicinal Biochemistry, Wellcome Research Laboratories, Research Triangle Park, NC
OSTI ID:
5998200
Journal Information:
Clin. Chem. (Winston-Salem, N.C.); (United States), Vol. 29:3
Country of Publication:
United States
Language:
English